MYND Life Sciences Inc. (MYND.CN)
| Previous Close | 0.0350 |
| Open | 0.0350 |
| Bid | 0.0200 x N/A |
| Ask | 0.0450 x N/A |
| Day's Range | 0.0350 - 0.0450 |
| 52 Week Range | 0.0150 - 0.1200 |
| Volume | |
| Avg. Volume | 19,363 |
| Market Cap | 2.152M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileMYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") today announces it has not made its payment obligations under its unsecured convertible debentures issued on September 8, 2021 with a total principal amount of $3,000,00
NewsfileMYND Life Sciences Inc. Has Management CTO Revoked
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") MYND is giving
NewsfileMYND Life Sciences Inc. Provides Default Status Report
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203") MYND is giv
